Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$127.60
-0.1%
$92.42
$73.04
$128.15
$8.24B0.831.61 million shs20.10 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$13.46
+0.3%
$10.66
$8.02
$18.80
$6.68B1.495.45 million shs5.66 million shs
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
$38.00
$37.94
$2.61
$38.90
$1.77B4.41.98 million shsN/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$110.32
+1.9%
$109.27
$95.49
$148.06
$6.80B0.38839,153 shs702,054 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
+26.34%+25.90%+22.12%+42.97%+21.06%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.19%+6.10%+37.87%+24.11%-24.01%
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
0.00%0.00%0.00%0.00%0.00%
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
+0.01%+0.20%-9.80%-22.07%+2.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.9741 of 5 stars
2.21.00.00.02.60.80.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.0573 of 5 stars
2.21.00.00.32.43.30.0
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
4.8926 of 5 stars
4.51.00.04.02.13.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.44
Hold$125.38-1.74% Downside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.1712.68% Upside
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
0.00
N/AN/AN/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
2.93
Moderate Buy$182.9365.82% Upside

Current Analyst Ratings Breakdown

Latest FPRX, JAZZ, ELAN, and BPMC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
6/3/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Peer Perform
6/3/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$150.00 ➝ $135.00
6/3/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
6/2/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$130.00 ➝ $129.00
6/2/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$135.00
6/2/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Neutral$128.00 ➝ $129.00
6/2/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold$130.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$182.00 ➝ $172.00
(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$562.12M14.66N/AN/A$4.67 per share27.32
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.51$2.78 per share4.84$12.63 per share1.07
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
$14.87M119.01N/AN/A$4.13 per share9.20
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.06B1.67$22.47 per share4.91$59.36 per share1.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A196.31N/A-13.19%-77.49%-20.84%7/30/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7433.6515.122.504.60%6.78%3.03%8/14/2025 (Estimated)
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
-$137.20M-$3.92N/AN/AN/A-554.71%-75.84%-49.08%N/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$414.83M$7.5015.545.901.0411.60%29.30%9.72%7/30/2025 (Estimated)

Latest FPRX, JAZZ, ELAN, and BPMC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/6/2025Q1 2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million
5/1/2025Q1 2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.15
2.85
2.80
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/A
5.35
5.35
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
1.46
4.26
3.74

Institutional Ownership

CompanyInstitutional Ownership
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
67.28%
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
64064.58 million61.22 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.65 million491.54 millionOptionable
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
8746.57 millionN/AOptionable
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
3,20061.65 million57.92 millionOptionable

Recent News About These Companies

Q2 Earnings Estimate for JAZZ Issued By Zacks Research

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$127.60 -0.19 (-0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$127.66 +0.06 (+0.05%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$13.46 +0.04 (+0.30%)
Closing price 03:59 PM Eastern
Extended Trading
$13.46 +0.00 (+0.04%)
As of 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Five Prime Therapeutics stock logo

Five Prime Therapeutics NASDAQ:FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$110.32 +2.03 (+1.87%)
Closing price 04:00 PM Eastern
Extended Trading
$110.36 +0.04 (+0.04%)
As of 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.